{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-25-000096","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2025-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.242482+00:00","generated_at":"2026-05-16T17:35:06.996381+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AnaptysBio sues Tesaro and GSK for breach of Jemperli collaboration; countersuit filed","bullets":["AnaptysBio alleges Tesaro breached exclusivity by conducting trials with competing PD-1 antagonists (e.g., Keytruda) and failing to maximize Jemperli return.","Tesaro countersued AnaptysBio on Nov 20, 2025, seeking injunctive relief; AnaptysBio calls claims meritless and will seek dismissal.","Parties agreed to expedited Delaware Chancery Court schedule; trial anticipated July 2026.","Milestone and royalty payments under Collaboration Agreement remain due during litigation."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-25-000096","json":"https://secwatch.observer/filing/0001370053-25-000096.json","markdown":"https://secwatch.observer/filing/0001370053-25-000096.md","text":"https://secwatch.observer/filing/0001370053-25-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000096/0001370053-25-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000096/anab-20251120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:35:06.996381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}